secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001213900-25-083719
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals granted 180-day Nasdaq extension to meet $1.00 bid price rule by March 2, 2026
--------------------------------------------------------------------------------

- Received Nasdaq extension until March 2, 2026 to regain compliance with minimum $1.00 bid price requirement.
- Initial 180-day compliance period ended September 1, 2025; extension granted due to meeting other listing criteria.
- Company must maintain closing bid ≥ $1.00 for 10 consecutive business days before deadline.
- If necessary, company will consider a reverse stock split to cure deficiency.
- No immediate effect on trading; stock continues on Nasdaq Capital Market under symbol ADIL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025083719/0001213900-25-083719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025083719/ea0255741-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-083719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer